atrasentan

09/04/2015 - "In the Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan/JAPAN trials, atrasentan-associated fluid retention was more likely in patients with diabetes and nephropathy who had lower eGFR or received a higher dose of atrasentan. "
10/15/2012 - "Atrasentan, a highly selective ETAR antagonist, reduces albuminuria in patients with DN. "
04/01/2011 - "In summary, atrasentan, at the doses tested, is generally safe and effective in reducing residual albuminuria and may ultimately improve renal outcomes in patients with type 2 diabetic nephropathy."
09/04/2015 - "Finding that albuminuria reduction was not associated with changes in body weight and Hb suggests that the albuminuria-reducing efficacy of atrasentan is not impaired by fluid retention."
05/01/2014 - "In conclusion, atrasentan reduced albuminuria and improved BP and lipid spectrum with manageable fluid overload-related adverse events in patients with type 2 diabetic nephropathy receiving RAS inhibitors."

04/15/2010 - "Here we evaluate the efficacy of atrasentan in a mouse model of prostate cancer metastatic colonization. "
05/01/2006 - "Atrasentan clinical trials demonstrated a statistically significant difference in the prostate cancer-specific QOL in favor of atrasentan (p=.032) and an increased quality-adjusted time to progression in men with HRPC. "
02/01/2003 - "Preliminary results from clinical trials, such as those with atrasentan--an ET(A)-receptor antagonist--in prostate cancer, are encouraging. "
01/15/2014 - "Atrasentan of no benefit to men with metastatic prostate cancer."
03/01/2010 - "The clinical investigation of an orally bioavailable ET antagonist, atrasentan, in prostate cancer, is encouraging. "

01/01/2011 - "Another very recent randomized, double-blind, placebo-controlled trial of subjects with diabetic nephropathy also provided evidence for a specific antiproteinuric effect of the ET receptor antagonist atrasentan on top of an already existing blockade of the renin-angiotensin system. "
04/01/2011 - "In summary, atrasentan, at the doses tested, is generally safe and effective in reducing residual albuminuria and may ultimately improve renal outcomes in patients with type 2 diabetic nephropathy."
05/01/2014 - "In conclusion, atrasentan reduced albuminuria and improved BP and lipid spectrum with manageable fluid overload-related adverse events in patients with type 2 diabetic nephropathy receiving RAS inhibitors."
09/04/2015 - "Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy."
04/01/2011 - "Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy."

04/01/2008 - "Atrasentan also substantially reduced cardiac hypertrophy, proteinuria, glomerulosclerosis and left ventricle ET-1 content. "
09/01/2006 - "Atrasentan substantially reduced proteinuria, cardiac hypertrophy, glomerulosclerosis and left ventricular ET-1 tissue concentration on both diets. "
01/01/2013 - "Therefore, we conclude that selective blockade of ETA by atrasentan has no effect on preventing or ameliorating proteinuria and kidney injury in adriamycin nephropathy. "
07/01/2006 - "5. Atrasentan reduced diabetic urine flow, proteinuria and plasma creatinine levels, but creatinine clearance was not significantly altered. "
01/01/2013 - "In this study, we evaluated the efficacy of ETA blockade by atrasentan in ameliorating proteinuria and kidney injury in murine adriamycin nephropathy, a model of human focal segmental glomerulosclerosis. "

11/01/2004 - "on day 1) markedly inhibited HEY tumors, atrasentan was very effective in potentiating this effect, with partial or complete tumor regression. "
08/01/2003 - "After 28 days, patients without objective signs of tumor progression were eligible to continue atrasentan in an extension study. "
04/15/2002 - "This study evaluated the safety, pharmacokinetics, and maximum-tolerated dose of atrasentan in cancer patients. "
10/01/2009 - "Although Atrasentan had no independent effect on the growth of HT29 tumors, Atrasentan combined with 20 Gy radiation led to a modest but significant increase in tumor growth delay compared to radiation alone."
03/01/2008 - "atrasentan, a potent, selective ET(A)R antagonist, has a direct effect on tumor proliferation, apoptosis, and angiogenesis. "